Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

This report describes a case of a 19-year-old woman experiencing severe recurrent angioedema with airway issues, leading to multiple emergency visits and unsuccessful treatment with typical steroid-sparing agents.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

This review of SVF treatment for androgenetic alopecia found a significant increase in hair density across studies with no serious adverse events, but calls for standardized protocols and further research.

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.

This article summarizes a meeting of the American Board of Hair Restoration Surgery's Board of Directors to discuss future plans, but does not report new experimental results.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study in ND-GFP transgenic mice found doxorubicin inhibited both tumor angiogenesis and growth, visualized through dual-color fluorescence imaging of nascent blood vessels and melanoma cell lines.

This case report describes a young adult female with late-stage Vogt-Koyanagi-Harada disease featuring panuveitis, retinal detachment, hearing loss, alopecia, and vitiligo, who was successfully treated in a hospital.

This scoping review aims to map current knowledge about treatment strategies for alopecia caused by VPA (valproic acid) across various patient groups, identifying reported management strategies, supporting evidence, observed outcomes, and areas needing further research, but results are not provided.

In this study, prenatal ultrasonography was found to be a valuable tool for screening ectodermal dysplasia during pregnancy, and a new EDA gene variant associated with X-linked hypohidrotic ectodermal dysplasia was identified, aiding in more accurate diagnoses and reproductive decision-making.

This case report describes a rare instance of alopecia areata linked to nivolumab treatment in a patient with hepatocellular carcinoma.

In this study, researchers developed a mouse model of scarring alopecia and observed significant reductions in CD200R expression in affected skin, potentially linking this signaling pathway to immune attacks on hair follicles and suggesting new treatment targets for scarring hair loss.

In this study, researchers found that both the EU-TIRADS and Bethesda systems exhibited high specificity but suboptimal sensitivity for predicting thyroid nodule malignancy in patients who underwent surgery, with Bethesda system showing particularly high specificity in this postoperative population.

This case report describes a 30-year-old Brazilian male who developed vitiligo lesions following diphencyprone therapy for alopecia areata.

This study found that pediatric cancer patients at Muhimbili National Hospital commonly experienced adverse drug reactions during chemotherapy, despite drug prescribing patterns aligning with essential medicine lists.

This study observed that two patients treated with interferon α-2b and ribavirin for chronic hepatitis C experienced complete and reversible straightening of their natural curly hair, which recurred with treatment resumption.

This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.

Raltegravir may cause hair loss in some patients.

This case report describes a 69-year-old man diagnosed with stage 3 acute kidney injury secondary to new IgG kappa light chain multiple myeloma, where treatment with bortezomib-based therapy showed potential for kidney function salvage.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study found that applying BPM 31543 twice daily was safe, well-tolerated, and showed signs of reducing chemotherapy-induced alopecia in women receiving taxane-based chemotherapy.

This article describes the skin changes seen in acute and chronic graft-vs-host reactions after bone marrow transplantation, highlighting the potential for early recognition due to the visibility of these changes, but reports no new clinical results.

In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

This study reports that a single injection of stromal vascular fraction (SVF) cells into the scalp of patients with androgenetic alopecia significantly increased hair density and thickness within 3 to 6 months, with no observed side effects.

This study confirms known risks of cladribine and reveals potential new safety concerns, emphasizing the need for careful monitoring for early acute toxicity.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.